If you have been reading about melanocortin and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-12-07. Numbers and descriptions here follow the published literature rather than marketing material.
Development of the peptide passed through several delivery formats, including an intranasal version tested in early trials and an injectable version that entered later clinical study. Regulatory approval for a subcutaneous product in the United States was granted in 2019 after review of controlled trials in premenopausal women. Outside the clinic, the compound circulates in research and non-pharmaceutical markets under its code name, where identity and purity vary considerably between suppliers. Synonyms appearing across technical literature include bremelanotide, PT-141, and Palatin 141.
PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide developed as a melanocortin receptor agonist. The peptide contains seven amino acids with an internal lactam bridge that constrains the backbone into a stable ring. Cyclisation of this kind improves resistance to enzymatic degradation relative to linear analogues. The compound was first explored for effects on melanin production, because several melanocortin receptors influence pigmentation. Its later association with sexual desire emerged from observations made during that early work, and the molecule became the subject of a separate development programme.
From a pharmacokinetic standpoint, the peptide is usually delivered by injection because oral bioavailability is very low; proteases in the digestive tract degrade it rapidly. After subcutaneous administration, plasma concentrations reach a peak within roughly one hour. Its elimination half-life is relatively short, with most reports placing it in the range of a few hours. Nasal formulations have also been examined, though absorption varies widely between individuals. Metabolism proceeds mainly through peptidase cleavage, and the resulting products are excreted by the kidneys.
PT-141 initiates cellular signaling by binding to specific subtypes within the melanocortin receptor family. These receptors belong to the G protein-coupled receptor superfamily, and activation raises intracellular cyclic adenosine monophosphate levels. This cascade ultimately influences neuronal circuits in the central nervous system that are associated with sexual desire and arousal. Research indicates the compound's action concentrates in hypothalamic regions rather than peripheral tissues, which helps explain some observed pharmacological features. The selectivity of receptor binding underlies its functional differences.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Cyclic heptapeptide | Synthetic melanocortin analogue |
| Molecular formula | C50H68N14O10 | Corresponds to a mass near 1025 daltons |
| Appearance | White to off-white powder | Lyophilised solid before reconstitution |
| Solubility | Soluble in water and polar solvents | Poor solubility in nonpolar media |
| Common synonyms | Bremelanotide, PT-141 | Code name and international name used interchangeably |
Bremelanotide acts as an agonist at several melanocortin receptors, with the strongest reported activity at MC4R and measurable activity at MC1R and MC3R. Because MC4R is expressed in hypothalamic and limbic circuits, the proposed mechanism links receptor activation to modulation of central pathways involved in desire rather than to direct effects on peripheral genital tissue. The precise downstream steps remain incompletely characterized, and evidence for the involvement of specific neurotransmitters is suggestive rather than settled. Nausea and blood pressure elevation reported during trials are consistent with melanocortin signaling outside the intended target circuit.
Compared with melanotan II, bremelanotide is a smaller cyclic peptide with a more constrained backbone, which affects receptor selectivity and metabolic stability. Published descriptions give a plasma half-life on the order of a few hours after subcutaneous administration, with elimination through hepatic and renal routes and limited plasma protein binding. Central access is inferred from effects observed in animal models, although direct measurement in humans is limited. Handling and storage requirements follow from the peptide backbone, which is susceptible to hydrolysis and oxidation.
The melanocortin system comprises five G protein-coupled receptors, designated MC1 through MC5, that signal mainly through cyclic AMP accumulation. MC1R and MC2R are associated with pigmentation and adrenal steroid production, while MC3R and MC4R are expressed in the central nervous system and influence energy balance and behavior. MC5R appears in exocrine tissues. Natural agonists include alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone, and endogenous antagonists such as agouti-related protein modulate the same sites. This receptor family provides the framework within which bremelanotide activity is described.
PT-141 is a synthetic cyclic heptapeptide whose development code is bremelanotide. It belongs to the class of melanocortin receptor agonists and acts by mimicking endogenous peptide hormones. The compound originated from research on melanotan II, where investigators exploring derivatives found distinct pharmacological features. Unlike the parent compound, PT-141 showed effects on pathways related to sexual desire and function in early studies, prompting its development as a separate candidate. Its molecular design aimed to separate receptor activity from pigmentary effects.
The molecular backbone consists of seven amino acid residues joined into a ring through a disulfide bridge. This cyclic conformation is critical for receptor binding. The sequence includes an acetylated N-terminus and an amidated C-terminus, modifications that improve resistance to enzymatic breakdown. One residue is in the D-configuration, a feature that further stabilizes the peptide against protease activity. Together, the ring structure and specific stereochemistry determine selectivity among melanocortin receptor subtypes.
Early work on melanocortin analogs in the 1980s and 1990s produced peptides intended to influence pigmentation and appetite. One of these, melanotan II, was observed to affect sexual desire as an incidental finding in self-administration reports. Researchers then pursued analogs with altered receptor selectivity and improved handling characteristics, and PT-141 emerged from that program in the late 1990s. The development path moved from dermatology and metabolism toward a central nervous system application, a shift that shaped both trial designs and the eventual label.
Regulatory review of bremelanotide concluded in 2019 with approval in the United States for a defined indication in premenopausal women. The reviewed formulation is a single-use prefilled autoinjector given subcutaneously, and its label carries cardiovascular monitoring language tied to blood pressure changes recorded during trials. Availability outside the approving jurisdiction varies, and in several countries the compound remains unapproved or is handled as a prescription-only item. Compounded and research-grade material also circulates, and it differs from the reviewed product in purity, characterization, and chain of custody.
Bremelanotide is a synthetic cyclic heptapeptide developed under the research code PT-141. The code reflects its position in an internal compound series rather than a chemical classification, and the name bremelanotide was later adopted for regulatory filings. Structurally it belongs to the melanocortin peptide family and shares a core sequence motif with alpha-melanocyte-stimulating hormone. The compound is supplied as an acetate salt in aqueous solution for injection. In reference literature it is indexed under both the code and the generic name, a dual listing that can complicate database searches.
Whether the behavioral effect originates centrally, peripherally, or through both remains an active question. Animal experiments using receptor antagonists and site-specific injections point toward hypothalamic melanocortin circuits as a key locus, but translating those findings to humans is not straightforward. Blood pressure changes observed in trials suggest a vascular component that may be peripherally mediated. The relationship between receptor occupancy and reported effect has not been mapped in humans, and no validated biomarker predicts response. This gap makes it difficult to explain individual variability on pharmacological grounds alone.
Bremelanotide acts as an agonist at melanocortin receptors, a family of five G-protein-coupled receptors labeled MC1 through MC5. Binding studies indicate activity at several of these subtypes rather than strict selectivity for one. Signalling proceeds mainly through Gs-mediated activation of adenylyl cyclase, raising intracellular cyclic AMP. The MC4 receptor, expressed in hypothalamic and limbic circuits, is widely regarded as the subtype most relevant to sexual response. Because the molecule is not subtype-selective, effects at other melanocortin receptors are expected and are used to explain some observed side effects.
The peptide contains seven amino acids arranged in a ring, closed by a lactam bridge between a side-chain acid and an amine. This cyclic constraint holds the backbone in a defined conformation and increases resistance to enzymatic breakdown relative to linear analogs. N-terminal acetylation and a C-terminal amide further protect the molecule from exopeptidases. The result is a compound with a comparatively long circulation time for a small peptide. Structural modification of the bridge alters receptor affinity, which is one reason analogs in this family differ in their subtype preferences.
During the visit to the archives, Xi said that "over the past 250 years, the American people have pursued the American Dream and built a prosperous country and a beautiful home on the North American continent" while "Chinese people, inheriting 5,000 years of Chinese civilization, have continued to make new achievements on the new journey toward realizing the Chinese Dream of the great rejuvenation of the Chinese nation". He said while "China and the United States have different histories and cultures, social systems and development paths", the "people of the two countries share the same aspiration for a better life despite the differences". Trump told reporters that "We’re just comparing. Ours goes 250 years. Which is great, and we’re proud of. Theirs goes 6,000 years. So there’s a little difference between 6,000 and 250. But we’re very proud of our 250." Before the visit finished, Trump gifted Xi a photo album of the trip. Afterwards, Xi and Peng left for Joint Base Andrews for their red carpet departure, with representatives of overseas Chinese and international students waving the Chinese and American flags on the road to on way to the airport. Senior US government officials saw them off at the airport, and a 21-gun salute was fired. They then onboarded a plane bound for Beijing, concluding the state visit. They returned to China on the afternoon of September 26.
=== Hospitals === Most clinical teaching takes place in facilities operated by UNC Health, primarily within the UNC Medical Center complex at the southern tip of the UNC campus. The complex comprises five healthcare facilities collectively known as UNC Hospitals, including North Carolina Memorial Hospital, North Carolina Children’s Hospital, North Carolina Women’s Hospital, North Carolina Neurosciences Hospital, and North Carolina Cancer Hospital. In 2024, the North Carolina Surgical Hospital was opened, featuring 26 new surgical spaces and 80 inpatient rooms. Together, these facilities offer over 1,000 inpatient beds and are ranked as the 2nd best hospital in the state of North Carolina. Additional hospitals and outpatient clinics in the area are also used for training, including the Ambulatory Care Center, the Family Medicine Building, UNC Hillsborough, and UNC Chatham. During the Application Phase (third year) of the school's MD program, students will be matched into one of six regions located across the state of North Carolina to complete their clinical clerkships at local facilities, including:
== Erinacines Z1,Z2 == Z1- Promote PC12 cell differentiation and neurite growth(potent cytotoxicity against HL-60 cell lines: IC50: 8.9 μmol/L) Z2- Promote PC12 cell differentiation and neurite growth(potent cytotoxicity against HL-60 cell lines: IC50: 0.5 μmol/)
== Characteristics of drugs candidate to therapeutic drug monitoring == In pharmacotherapy, many medications are used without monitoring of blood levels, as their dosage can generally be varied according to the clinical response that a patient gets to that substance. For certain drugs, this is impracticable, while insufficient levels will lead to undertreatment or resistance, and excessive levels can lead to toxicity and tissue damage. Indications in favor of therapeutic drug monitoring include:
Most taste buds on the tongue and other regions of the mouth can detect umami taste, irrespective of their location. (The tongue map in which different tastes are distributed in different regions of the tongue is a common misconception.) Biochemical studies have identified the taste receptors responsible for the sense of umami as modified forms of mGluR4, mGluR1, and taste receptor type 1 (TAS1R1 + TAS1R3), all of which have been found in all regions of the tongue bearing taste buds. These receptors are also found in some regions of the duodenum. A 2009 review corroborated the acceptance of these receptors, stating, "Recent molecular biological studies have now identified strong candidates for umami receptors, including the heterodimer TAS1R1/TAS1R3, and truncated type 1 and 4 metabotropic glutamate receptors missing most of the N-terminal extracellular domain (taste-mGluR4 and truncated-mGluR1) and brain-mGluR4." Receptors mGluR1 and mGluR4 are specific to glutamate whereas TAS1R1 and TAS1R3 are responsible for the synergism already described by Akira Kuninaka in 1957. However, as of this date, the specific role of each type of receptor in taste bud cells remained unclear. All three receptors work together to produce the taste sensation.
Sources: en.wikipedia.org
== Music and lyrics == With songs written primarily on the road, the material is darker than Facelift. "We did a lot of soul searching on this album. There's a lot of intense feelings." Cantrell said, "We deal with our daily demons through music. All of the poison that builds up during the day we cleanse when we play". Drug use was front and center as a lyrical theme on the album. Three tracks ("Junkhead", "God Smack", and "Hate to Feel") specifically reference heroin use and its effects. Staley revealed that the album is semi-conceptual and that there are two basic themes in it. The first theme is about "dealing with kind of a personal anguish and turmoil, which turns into drugs to ease that pain, and being confident that that was the answer in a way. Then later on the songs start to slip down closer and closer to hell, and then he figures out that drugs were not, and are not, the way to ease that pain. Basically, it's the whole story of the last three years of my life." Staley described the other theme as being about "painful relationships and involvements with persons." Staley later expressed regret about the lyrical content of some songs on Dirt, explaining, "I wrote about drugs, and I didn't think I was being unsafe or careless by writing about them ... I didn't want my fans to think that heroin was cool. But then I've had fans come up to me and give me the thumbs up, telling me they're high. That's exactly what I didn't want to happen." Cantrell said in 2013: "That darkness was always part of the band, but it wasn't all about that.
== Mechanism of action == Levosimendan is a calcium sensitizer — it increases the sensitivity of the heart to calcium, thus increasing cardiac contractility without a rise in intracellular calcium. Levosimendan exerts its positive inotropic effect by increasing calcium sensitivity of myocytes by binding to cardiac troponin C in a calcium-dependent manner. It also has a vasodilatory effect, by opening adenosine triphosphate (ATP)-sensitive potassium channels in vascular smooth muscle to cause smooth muscle relaxation. The combined inotropic and vasodilatory actions result in an increased force of contraction, decreased preload and decreased afterload. Moreover, by opening also the mitochondrial (ATP)-sensitive potassium channels in cardiomyocytes, the drug exerts a cardioprotective effect.
Carbonyl sulfide is the chemical compound with the linear formula O=C=S. It is a colorless flammable gas with an unpleasant odor. It is a linear molecule consisting of a carbonyl double bonded to a sulfur atom. Carbonyl sulfide can be considered to be intermediate between carbon dioxide and carbon disulfide, both of which are valence isoelectronic with it.
=== Medicine === Nitrogen heterocycles in general, and pyridines in particular, are widely used structural motifs in pharmaceuticals. In a study published in 2021, the structures of all pharmaceuticals approved by the Food and Drug Administration in the United States were analyzed with respect to nitrogen heterocycles. Sixty-two of these compounds contained a pyridine unit, making pyridines the second most common nitrogen heterocycles after piperidines. Most pyridine rings were mono- or disubstituted, with substituents in the 2-position occurring most frequently. Pyridine-containing pharmaceuticals include a number of structurally very similar antihistamines, such as chlorphenamine and brompheniramine. Proton pump inhibitors such as pantoprazole contain a pyridine ring as an important structural element. These active substances are prodrugs that, in addition to the pyridine ring, contain a sulfoxide and a benzimidazole unit. The actual active species is a cyclic sulfenamide. To generate this species, the benzimidazole moiety must be activated by protonation, whereas the pyridine must be deprotonated so that it can act as a nucleophile. Consequently, substituents that modulate the PKs values of the nitrogen atoms or enhance the nucleophilicity of the pyridine nitrogen are of crucial importance. In addition to pantoprazole, this class of drugs includes omeprazole, lansoprazole, and rabeprazole.
Sources: en.wikipedia.org
PT-141 is a laboratory code for bremelanotide, a synthetic peptide that activates melanocortin receptors. It has been developed both as an injectable pharmaceutical product and as a research chemical. The two contexts differ sharply in how identity, purity, and dosing are controlled.
It is neither a steroid nor a naturally occurring human hormone. Bremelanotide is a manufactured peptide that mimics part of the melanocortin signalling system by binding receptor proteins. Its effects come from receptor activation, not from replacing a circulating hormone.
The internal lactam bridge locks the peptide into a defined shape, which raises receptor affinity and slows enzymatic breakdown. Linear versions of the same sequence are less stable and bind more weakly. Ring geometry is therefore central to how the molecule behaves in the body.
It primarily activates specific subtypes in the melanocortin receptor family. These receptors are G protein-coupled and mediate signaling mainly within the central nervous system.